Neuroprotective effects of lutein in the retina

Current Pharmaceutical Design

Volumn 18, Issue 1, 2012, Pages 51-56

  Ozawa, Yoko ^a,b   Sasaki, Mariko ^a,b   Takahashi, Noriko ^a,b   Kamoshita, Mamoru ^a,b   Miyake, Seiji ^a   Tsubota, Kazuo ^b  

^a Laboratory of Retinal Cell Biology   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BDNF; DNA damage; Lutein; Neuroprotection; Oxidative stress; Protein degradation; Retina; Synaptophysin; Ubiquitin proteasome system; Visual function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; PROTEIN; REACTIVE OXYGEN METABOLITE; RHODOPSIN; STREPTOZOCIN; SYNAPTOPHYSIN; XANTHOPHYLL; ZEAXANTHIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL DEATH; CELL SURVIVAL; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; ENDOTOXIN INDUCED UVEITIS; HUMAN; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LIGHT; LIPID PEROXIDATION; NERVE CELL; NERVE CELL INHIBITION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; RETINA; RETINA DEGENERATION; RETINITIS; REVIEW; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UVEITIS; VISION; VISUAL DISORDER;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HUMANS; LUTEIN; MICE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RETINA; RETINAL DISEASES;

EID: 84855841572     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212798919101     Document Type: Review

References (44)

1. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38: 1802-11.
2. Khachik F, Carvalho L, Bernstein PS, Muir GJ, Zhao DY, Katz NB. Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Exp Biol Med 2002; 227: 845-51.
3. Yonekura L, Nagao A. Intestinal absorption of dietary carotenoids. Mol Nutr Food Res 2007; 51: 107-15.
4. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Invest Ophthalmol Vis Sci 1993; 34: 2033-40.
5. Rapp LM, Maple SS, Choi JH. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest Ophthalmol Vis Sci 2000; 41: 1200-9.
6. Bhosale P, Li B, Sharifzadeh M, et al. Purification and partial characterization of a lutein-binding protein from human retina. Biochem 2009; 48: 4798-807.
7. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Inter 2008; 8: 36-49.
8. Ziegler J, Facchini PJ, Geissler R, et al. Evolution of morphine biosynthesis in opium poppy. Phytochem 2009; 70: 1696-707.
9. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. Jama 1994; 272: 1413-20.
10. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007; 125: 1225-32.
11. Richer S, Stiles W, Statkute L, et al. Double-masked, placebocontrolled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75: 216-30.
12. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmol 2008; 115: 334-41.
13. Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group. Arch Ophthalmol 1993; 111: 104-9.
14. Michikawa T, Ishida S, Nishiwaki Y, et al. Serum antioxidants and age-related macular degeneration among older Japanese. Asia Pac J Clin Nutr 2009; 18: 1-7.
15. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001; 42: 235-40.
16. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107: 2224-32.
17. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
18. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-21.
19. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9.
20. Sasaki M, Ozawa Y, Kurihara T, et al. Neuroprotective effect of an antioxidant, lutein, during retinal inflammation. Invest Ophthalmol Vis Sci 2009; 50: 1433-9.
21. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008; 57: 2191-8.
22. Nagai N, Oike Y, Noda K, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005; 46: 2925-31.
23. Ozawa Y, Kurihara T, Tsubota K, Okano H. Regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection. J Ophthalmol 2011; 2011: 506137.
24. Ozawa Y, Nakao K, Kurihara T, et al. Roles of STAT3/SOCS3 pathway in regulating the visual function and ubiquitinproteasome-dependent degradation of rhodopsin during retinal inflammation. J Biol Chem 2008; 283: 24561-70.
25. Lem J, Krasnoperova NV, Calvert PD, et al. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci USA 1999; 96: 736-41.
26. Ozawa Y, Nakao K, Shimazaki T, et al. SOCS3 is required to temporally fine-tune photoreceptor cell differentiation. Dev Biol 2007; 303: 591-600.
27. Madamanchi NR, Li S, Patterson C, Runge MS. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler Thromb Vasc Biol 2001; 21: 321-6.
28. Jin XH, Ohgami K, Shiratori K, et al. Inhibitory effects of lutein on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci 2006; 47: 2562-8.
29. Izumi-Nagai K, Nagai N, Ohgami K, et al. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol 2007; 27: 2555-62.
30. Kurihara T, Ozawa Y, Shinoda K, et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 2006; 47: 5545-52.
31. Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol 2006; 50: 367-73.
32. Yonemura D, Tsuzuki K, Aoki T. Clinical importance of the oscillatory potential in the human ERG. Acta Ophthalmologica 1962; Suppl 70: 115-123.
33. Tarpey PS, Smith R, Pleasance E, et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 2009; 41: 535-43.
34. Zhan SS, Beyreuther K, Schmitt HP. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia (Basel, Switzerland) 1993; 4: 66-74.
35. Carthew RW, Neufeld TP, Rubin GM. Identification of genes that interact with the sina gene in Drosophila eye development. Proc Natl Acad Sci USA 1994; 91: 11689-93.
36. Wheeler TC, Chin LS, Li Y, Roudabush FL, Li L. Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J Biol Chem 2002; 277: 10273-82.
37. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetesinduced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007; 48: 4342-50.
38. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010; 53: 971-9.
39. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth factors 2004; 22: 123-31.
40. Kohara K, Kitamura A, Morishima M, Tsumoto T. Activitydependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. Science 2001; 291: 2419-23.
41. Cortina MS, Gordon WC, Lukiw WJ, Bazan NG. DNA repair in photoreceptor survival. Mol Neurobiol 2003; 28: 111-22.
42. Gordon WC, Casey DM, Lukiw WJ, Bazan NG. DNA damage and repair in light-induced photoreceptor degeneration. Invest Ophthalmol Vis Sci 2002; 43: 3511-21.
43. Specht S, Leffak M, Darrow RM, Organisciak DT. Damage to rat retinal DNA induced in vivo by visible light. Photochem Photobiol 1999; 69: 91-8.
44. Sasaki M, Yuki K, Kurihara T, et al. Biological role of lutein in the light-induced retinal degeneration. J Nutr Biochem 2011; Jun 8. [Epub ahead of print].